Skip to content
AnalystLens

BBIO · BridgeBio Pharma

7 filings

10-K

BBIO 10-K Annual Reports

BridgeBio Pharma - 7 annual reports

Filing record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Material agreement8-K · Mar ’20Mar ’20
  2. Leadership change8-K · Aug ’21Aug ’21
  3. Material agreement8-K · Mar ’23Mar ’23
  4. FY2025 annual report10-K · Feb ’26Feb ’26
  1. 2025

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2025

    BridgeBio Pharma, Inc. (BBIO) reports that it is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model. Its largest product, Attruby (acoramidis) for ATTR-CM, generated $362.4 million in U.S. net product revenue in 2025, and total revenues, net were $502.1 million for 2025 compared with $221.9 million in 2024. The company still reported a net loss of $732.9 million for 2025 (versus $543.3 million in 2024), an accumulated deficit of $3.8 billion, and a working capital deficit position reflected in total stockholders' deficit of $2.08 billion at year-end. Cash, cash equivalents and marketable securities were $587.5 million as of December 31, 2025, and management states these resources plus Attruby revenue should fund operations for at least the next 12 months. The filing highlights substantial debt and royalty obligations: total consolidated indebtedness of $1.9 billion in convertible notes and deferred royalty obligations of $866.3 million. In January 2026 BridgeBio issued $632.5 million of 0.75% convertible senior notes due 2033. Pipeline catalysts include positive Phase 3 data for infigratinib in achondroplasia (PROPEL 3, February 2026), encaleret in ADH1 (CALIBRATE, October 2025) and BBP-418 in LGMD2I/R9 (FORTIFY interim analysis, October 2025), with NDA submissions planned for 2026 and an infigratinib MAA/NDA planned for the second half of 2026. Beyonttra (acoramidis) is commercialized ex-U.S. through partners Bayer (Europe) and Alexion (Japan). Investors should weigh the commercial ramp of Attruby and the late-stage pipeline against continued losses, heavy operating expenses (selling, general and administrative expenses rose to $531.2 million), reliance on third-party manufacturers, and the cost and dilution implications of its debt and royalty financings. Exposure to U.S. drug pricing reforms, including proposed GLOBE and GUARD models and most-favored-nation initiatives, is also flagged as a risk to future revenue.

    Feb 24, 2026
  2. 2024

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2024

    BridgeBio Pharma, Inc. reported a net loss of $543.3 million for 2024, compared with $653.3 million in 2023, as the company moved toward commercialization. Its first commercial product, Attruby (acoramidis), was approved by the FDA on November 22, 2024 for adults with ATTR-CM, and launched in the U.S. The European Commission approved acoramidis as Beyonttra on February 10, 2025, and Bayer plans a European launch in the first half of 2025. Revenue rose to $221.9 million in 2024 from $9.3 million in 2023, driven mainly by $207.7 million of upfront license and services revenue under the Bayer and Kyowa Kirin agreements. Net product revenue from Attruby was only $2.9 million, and the company states it has not yet generated substantial product revenue. The balance sheet carries significant leverage. Total consolidated indebtedness was $1.7 billion at December 31, 2024, including convertible notes and a senior secured term loan. The company also received $500.0 million under a Funding Agreement that carries a royalty of 5% of global Attruby net sales, which may rise to 10% in 2027, subject to a $950.0 million cap. Cash and cash equivalents were $681.1 million, and working capital was $566.3 million. The company states that cash and proceeds from Attruby revenue should fund operations for at least the next 12 months, and that the prior substantial doubt about going concern was resolved. Pipeline catalysts for 2025 include Phase 3 PROPEL 3 for low-dose infigratinib in achondroplasia, which completed enrollment in January 2025; Phase 3 FORTIFY interim analysis of BBP-418 for LGMD2I, with topline data expected in the second half of 2025; and a Phase 3 encaleret trial in ADH1, with topline results expected in the second half of 2025. The company's accumulated deficit reached $3.1 billion at year-end 2024.

    Feb 20, 2025
  3. 2023

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2023

    BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers. Its 10-K for fiscal 2023 reports a net loss of $653.3 million, compared with $484.7 million in 2022 and $586.5 million in 2021, and an accumulated deficit of $2.6 billion. Revenue fell to $9.3 million from $77.6 million, mainly because 2022 included license revenue from the Navire-BMS License Agreement. Research and development expense rose to $455.7 million from $399.5 million. The company reported cash, cash equivalents and restricted cash of $392.6 million, and it said these resources, together with its investment in equity securities, will fund operations for at least the next 12 months. The lead late-stage asset is acoramidis for ATTR-CM. The NDA was accepted by the FDA with a PDUFA date of November 29, 2024, and the MAA was accepted by the EMA. Three other programs are in Phase 3: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9. Subsequent to year-end, the company entered financing arrangements: a Funding Agreement under which purchasers would pay $500.0 million upon first FDA approval of acoramidis in exchange for 5% of global net sales (adjustable to 10% in 2027), and a Financing Agreement for a senior secured term loan of up to $750.0 million, with $450.0 million funded on January 17, 2024 to repay the prior Loan Agreement. Liquidity and leverage are significant: total consolidated indebtedness was $1.7 billion as of December 31, 2023, including the 2027 and 2029 convertible notes and the term loan. The Financing Agreement requires a minimum unrestricted cash balance of $70.0 million and restricts dividends and certain transactions. The company also disclosed a February 7, 2024 license of infigratinib in Japan to Kyowa Kirin for a $100.0 million upfront payment.

    Feb 22, 2024
  4. 2022

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2022

    BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded in 2015 to discover, create, test and deliver medicines for genetic diseases and cancers with clear genetic drivers. The company reports that it has created 15 INDs and had two products approved by the FDA (TRUSELTIQ and NULIBRY). Its net losses were $484.7 million in 2022, $586.5 million in 2021 and $505.5 million in 2020, with an accumulated deficit of $1.9 billion as of December 31, 2022. Revenue was $77.6 million in 2022, driven mainly by $74.7 million of license revenue from the Navire-BMS License Agreement, and the company sold its priority review voucher for gross proceeds of $110.0 million. The lead program, acoramidis for ATTR-CM, failed its Part A primary endpoint at Month 12 (6MWD p = 0.76), but the Part B 30-month outcomes readout is anticipated in mid-2023. The company also lists low-dose infigratinib for achondroplasia, encaleret for ADH1, BBP-418 for LGMD2I, BBP-631 for CAH and a KRAS inhibitor portfolio among its key programs. A January 2022 restructuring initiative cost $43.8 million in 2022, and the company expects further charges of $6.0 million to $9.0 million in 2023. As of December 31, 2022, total consolidated indebtedness was $1.7 billion, and cash, cash equivalents and marketable securities totaled $428.3 million. Management states these resources, together with restricted cash and equity securities, will fund operations for at least the next 12 months.

    Feb 23, 2023
  5. 2021

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2021

    BridgeBio Pharma, Inc. reported a net loss of $586.5 million for the year ended December 31, 2021, compared with $505.5 million in 2020 and $288.6 million in 2019, and an accumulated deficit of $1.4 billion. Total revenue was $69.7 million in 2021, consisting of $65.9 million in license revenue and $3.8 million in product sales, following $8.2 million in 2020. Research and development expenses rose to $451.0 million from $337.0 million, and selling, general and administrative expenses rose to $192.2 million from $145.7 million. The company had cash, cash equivalents and marketable securities of $787.5 million and an investment in equity securities of $49.1 million at year-end, and states it expects these to fund operations for at least the next 12 months. The company has two approved products, NULIBRY (fosdenopterin) and TRUSELTIQ (infigratinib). Its most significant pipeline event in the filing is the December 27, 2021 topline report that acoramidis missed its Part A primary endpoint at Month 12 (6MWD change, p = 0.76) in the Phase 3 ATTRibute-CM study. The company continues to expect top-line 30-month Part B outcomes in mid-2023. Other near-term catalysts described include PROPEL 2 initial infigratinib data in mid-2022, BBP-631 initial Phase 1/2 data in the second half of 2022, and BBP-418 Phase 2 top-line data in 2022. At year-end the company had total consolidated indebtedness of $1.7 billion, including $747.5 million of 2.25% convertible notes due 2029, $550.0 million of 2.50% convertible notes due 2027, and $450.0 million drawn under a November 2021 loan agreement, with a further $300.0 million tranche available until December 31, 2022 subject to clinical milestones. The filing also notes a $150.0 million share repurchase program completed in 2021 and that the Eidos Merger, closed January 26, 2021, was settled with approximately 26.2 million shares and $21.3 million in cash.

    Feb 25, 2022
  6. 2020

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2020

    BridgeBio Pharma, Inc. reported its 2020 annual results in this Form 10-K filed February 25, 2021. The company is a clinical-stage biopharmaceutical company focused on Mendelian diseases and genetically driven cancers. It has not generated product revenue. License revenue was $8.2 million in 2020, down from $40.6 million in 2019. Net loss was $505.5 million in 2020, compared with $288.6 million in 2019 and $169.5 million in 2018. The accumulated deficit reached $888.8 million at December 31, 2020. Research and development expense rose to $337.0 million and general and administrative expense to $145.7 million. At year-end, cash, cash equivalents and marketable securities totaled $607.1 million, and the company stated that this would fund operations for at least the next 12 months. Total consolidated indebtedness was $642.5 million, including $550.0 million of 2.50% convertible senior notes due 2027. In January 2021 the company completed its acquisition of Eidos Therapeutics, issued $717.5 million of 2.25% convertible notes due 2029, and reported that the 2029 notes generated net proceeds of approximately $731.7 million. Lead programs include acoramidis for ATTR cardiomyopathy, in a Phase 3 trial with top-line 6MWD data expected in late 2021 or early 2022; low-dose infigratinib for achondroplasia, with PROPEL 2 data expected in the second half of 2021; and infigratinib for cholangiocarcinoma, under an NDA with Priority Review.

    Feb 25, 2021
  7. 2019

    BridgeBio Pharma Annual Report, Year Ended Dec 31, 2019

    BridgeBio Pharma, Inc. (BBIO) is a clinical-stage biopharmaceutical company, founded in 2015, that is developing medicines for Mendelian diseases and genetically driven cancers through a decentralized structure in which each program sits in its own subsidiary. As of December 31, 2019, the company reported over 20 development programs, with four key value drivers: BBP-265 (AG10, Eidos) for ATTR, infigratinib (BBP-831) for FGFR-driven cancers and achondroplasia, BBP-631 for CAH, and BBP-454 for KRAS-driven cancers. The company has not generated product revenue; its only 2019 revenue was license revenue of $40.6 million, mainly from the Alexion license agreement for BBP-265 in Japan. The company incurred a net loss of $288.6 million in 2019, compared with $169.5 million in 2018 and $43.8 million in 2017, and had an accumulated deficit of $440.0 million. Research and development expense rose to $209.9 million from $140.1 million, and general and administrative expense rose to $94.4 million from $43.6 million. At year-end, cash, cash equivalents and marketable securities totaled $577.1 million, or $385.9 million excluding Eidos, and debt was $91.8 million net. The company stated that it expects its cash to fund operations for at least the next 12 months. Its July 2019 IPO on Nasdaq under the symbol BBIO raised net proceeds of approximately $366.2 million. Key near-term catalysts include the ongoing Phase 3 ATTRibute-CM trial of BBP-265 (12-month 6MWD data expected in 2021), planned NDA submission for infigratinib in second-line CCA in 2020, a Phase 3 first-line CCA trial, and an ATTR-PN Phase 3 start in the first half of 2020. The filing also discloses that the company identified material weaknesses in internal control in its 2017 audit and states that these were remediated as of December 31, 2019.

    Mar 3, 2020